2024
FRI-389 Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B
Wong R, Yang Z, Jou J, John B, Lim J, Cheung R. FRI-389 Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B. Journal Of Hepatology 2024, 80: s771. DOI: 10.1016/s0168-8278(24)02152-4.Peer-Reviewed Original Research
2020
Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
Lim JK, Chang AY, Zaman A, Martin P, Fernandez-Rodriguez CM, Korkmaz M, Rossi S, Ford JM, Noonan T, Cooney E, Navarro V, Colombato L. Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Journal Of Clinical And Translational Hepatology 2020, 8: 377-384. PMID: 33447520, PMCID: PMC7782110, DOI: 10.14218/jcth.2020.00039.Peer-Reviewed Original ResearchClinical outcome eventsHepatocellular carcinomaDiagnostic criteriaChronic hepatitis B virus infectionHepatitis B virus infectionPrimary study outcome measureHBV disease progressionNon-HCC malignanciesChronic hepatitis BB virus infectionStudy outcome measuresDisease progression eventsEvent adjudication committeePotential adverse effectsRandomized therapyAnalogue therapyHepatitis BProspective studyAdjudicated diagnosisAdjudication committeeMalignant neoplasmsDisease progressionEvent adjudicationOutcome eventsVirus infectionPrevalence of Chronic Hepatitis B Virus Infection in the United States.
Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. The American Journal Of Gastroenterology 2020, 115: 1429-1438. PMID: 32483003, DOI: 10.14309/ajg.0000000000000651.Peer-Reviewed Original ResearchConceptsChronic hepatitis B virus infectionHepatitis B virus infectionB virus infectionWorld Health OrganizationChronic HBVVirus infectionMajor global health problemChronic HBV infectionGlobal health problemHBV prevalenceHBV infectionHBV screeningLiver cirrhosisSubstantial morbidityLiver diseaseClinical complicationsHepatocellular carcinomaHealth problemsElimination planPrevalenceDisease FoundationHealth OrganizationInfectionPeer-reviewed literatureUnited States
2016
Disparities in hepatitis C testing in U.S. veterans born 1945–1965
Sarkar S, Esserman DA, Skanderson M, Levin FL, Justice AC, Lim JK. Disparities in hepatitis C testing in U.S. veterans born 1945–1965. Journal Of Hepatology 2016, 65: 259-265. PMID: 27130843, PMCID: PMC4955712, DOI: 10.1016/j.jhep.2016.04.012.Peer-Reviewed Original ResearchConceptsUnited States Preventative Services Task ForceHCV testingHCV antibodiesRisk factorsHepatitis C virus testingHepatitis C virus infectionHealth systemVeterans Administration Health SystemBirth cohort testingHCV testing practicesHepatitis C testingNational screening policyPositive HCV RNAPredictors of testingC virus infectionVA health systemAdvanced liver fibrosisVeterans Administration dataCorporate Data WarehouseHCV positivityHCV RNAAdvanced fibrosisHCV testLiver fibrosisVirus infection
2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. The Lancet 2014, 384: 1756-1765. PMID: 25078309, DOI: 10.1016/s0140-6736(14)61036-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesGenotypeHepacivirusHepatitis C, ChronicHeterocyclic Compounds, 3-RingHumansInterferon-alphaLiver Function TestsMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsReference ValuesRibavirinRisk AssessmentSeverity of Illness IndexSimeprevirSofosbuvirSulfonamidesTreatment OutcomeUridine MonophosphateConceptsTreatment-naive patientsAdverse eventsGroup 1Chronic HCV genotype 1 infectionHepatitis C virus genotype 1Grade 4 adverse eventsVirological response 12 weeksHCV genotype 1 infectionHepatitis C virus infectionC virus genotype 1C virus infectionCommon adverse eventsInterferon-free regimensSerious adverse eventsGenotype 1 infectionPrimary endpointWeek 12Study treatmentChronic infectionCohort 1Genotype 1Grade 3Virus infectionSafety dataAmylase concentration